强生(杨森) 临床试验
-
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
-
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Di
-
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non
-
Premedication to Reduce Amivantamab Associated Infusion Related Reactions
-
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With
-
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Pre
-
A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
-
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-B
-
A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CR
-
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
-
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
-
A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis
-
A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Vi
-
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
-
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-T
按公司浏览
辉瑞默沙东罗氏诺华阿斯利康强生(杨森)百时美施贵宝赛诺菲葛兰素史克礼来艾伯维安进拜耳勃林格殷格翰诺和诺德武田吉利德莫德纳BioNTech再生元福泰渤健第一三共安斯泰来卫材大冢施维雅因塞特赛特瑞恩三星Bioepis韩美药品柳韩洋行